Published in Med Inform (Lond) on December 18, 1986
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst (1998) 2.12
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol (2001) 1.64
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Association between Helicobacter pylori infection and pancreatic cancer. Oncology (1998) 1.49
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer (2003) 1.48
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie (2003) 1.41
Pemphigus erythematosus-like rash in a patient on penicillamine. Br Med J (1977) 1.39
Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol (1996) 1.38
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology (1999) 1.38
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer (1993) 1.26
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol (2009) 1.26
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer (2006) 1.22
Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluids. Ann Rheum Dis (1975) 1.19
CADIAG: approaches to computer-assisted medical diagnosis. Comput Biol Med (1985) 1.19
HER 2/neu protein expression in colorectal cancer. BMC Cancer (2006) 1.18
[Autoimmune phenomena in D-penicillamine therapy]. Acta Med Austriaca (1975) 1.17
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med (1994) 1.15
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer (2008) 1.12
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int (2005) 1.11
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer (2001) 1.09
Knowledge-based interpretation of toxoplasmosis serology test results including fuzzy temporal concepts--the ToxoNet system. Stud Health Technol Inform (2001) 1.09
Answering patients' needs: oral alternatives to intravenous therapy. Oncologist (2001) 1.06
Toxopert-I: knowledge-based automatic interpretation of serological tests for toxoplasmosis. Comput Methods Programs Biomed (1997) 1.05
Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost (2011) 1.05
Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE. Cancer (2000) 1.03
MONI: an intelligent database and monitoring system for surveillance of nosocomial infections. Medinfo (1995) 1.03
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep (1986) 1.03
HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis. J Rheumatol (1984) 1.02
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol (2008) 1.01
Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol (2003) 1.00
Seropositive rheumatoid arthritis associated with decreased diffusion capacity of the lung. Ann Rheum Dis (1976) 0.99
Demonstration of anticollagen antibodies in rheumatoid arthritis synovial fluids by 14C-radioimmunoassay. Arthritis Rheum (1978) 0.99
Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol (2000) 0.98
Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol (2002) 0.98
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys (2001) 0.97
Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res (1994) 0.96
Letter: Serum beta2-microglobulin and SLE. Arthritis Rheum (1976) 0.96
Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol (2001) 0.96
Lymphocyte transformation to denatured type I collagen and B lymphocyte alloantigens in rheumatoid arthritis. Arthritis Rheum (1980) 0.94
Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol (1992) 0.93
Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol (2003) 0.93
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie (2003) 0.92
Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer (2005) 0.92
Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer (1995) 0.92
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer (1999) 0.91
Acute tumor pain in patients with head and neck cancer treated with vinorelbine. J Natl Cancer Inst (1996) 0.90
Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer (2002) 0.90
Feasibility analysis of a case-based reasoning system for automated detection of coronary heart disease from myocardial scintigrams. Artif Intell Med (1997) 0.90
MDR1 gene expression in primary colorectal carcinomas. Br J Cancer (1993) 0.89
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer (2000) 0.89
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol (2003) 0.89
Coincidence of Crohn's disease and a high-risk gastrointestinal stromal tumor of the terminal ileum. Digestion (1999) 0.88
Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer (2010) 0.87
[High dosage vitamin E therapy in patients with activated arthrosis]. Z Rheumatol (1991) 0.87
Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med (1995) 0.87
Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. Scand J Rheumatol (1994) 0.87
Human colon cancer cell lines secrete alpha TGF-like activity. Br J Cancer (1987) 0.86
Interferon in essential thrombocythaemia. Br J Haematol (1991) 0.86
A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach. Cancer (1993) 0.86
Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology (2001) 0.86
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer (2000) 0.85
Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop (Belle Mead NJ) (1999) 0.85
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med (1998) 0.85
Tomographic examinations of sacroiliac joints in adult patients with rheumatoid arthritis. J Rheumatol (1980) 0.84
123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer (1998) 0.84
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol (1998) 0.84
Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int (2007) 0.83
Problems in establishing the medical expert systems CADIAG-1 and CADIAG-2 in rheumatology. J Med Syst (1986) 0.83
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol (2000) 0.83
[Leukocytic changes under treatment with L-asparaginase]. Wien Med Wochenschr (1971) 0.83
Ondansetron for pruritus due to cholestasis. N Engl J Med (1994) 0.82
Oxaliplatin-induced fever and release of IL-6. Oncology (2000) 0.82
Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology (2001) 0.82
Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol (1995) 0.82
[Knowledge-based diagnosis and therapeutic recommendations with fuzzy-set theory methods in patients with acute lung failure (ARDS)]. Anasthesiol Intensivmed Notfallmed Schmerzther (1999) 0.82
Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res (2001) 0.82
Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. J Rheumatol (1993) 0.82
Risks of operation in patients over 80. Geriatrics (1973) 0.82
Copper in ankylosing spondylitis and rheumatoid arthritis. Scand J Rheumatol (1978) 0.82
HLA-B8 in caucasian patients with systemic lupus erythematosus. Scand J Rheumatol (1978) 0.82
Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. Eur J Cancer (1995) 0.82
Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer (1995) 0.82
Technetium-99m-galactosyl-neoglycoalbumin combined with iodine-123-Tyr-(A14)-insulin visualizes human hepatocellular carcinomas. J Nucl Med (1995) 0.82
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med (1998) 0.81
[Pulmonary manifestations in connective tissue diseases (author's transl)]. Prax Klin Pneumol (1979) 0.81
In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol (1986) 0.81